Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 24


Key role of nuclear factor-κB in the cellular pharmacokinetics of adriamycin in MCF-7/Adr cells: the potential mechanism for synergy with 20(S)-ginsenoside Rh2.

Zhang J, Lu M, Zhou F, Sun H, Hao G, Wu X, Wang G.

Drug Metab Dispos. 2012 Oct;40(10):1900-8. doi: 10.1124/dmd.112.045187.


Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.

Knappskog S, Chrisanthar R, Løkkevik E, Anker G, Østenstad B, Lundgren S, Risberg T, Mjaaland I, Leirvaag B, Miletic H, Lønning PE.

Breast Cancer Res. 2012 Mar 15;14(2):R47.


Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification.

Betof AS, Rabbani ZN, Hardee ME, Kim SJ, Broadwater G, Bentley RC, Snyder SA, Vujaskovic Z, Oosterwijk E, Harris LN, Horton JK, Dewhirst MW, Blackwell KL.

Br J Cancer. 2012 Feb 28;106(5):916-22. doi: 10.1038/bjc.2012.32.


PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.

Wang L, Zhang Q, Zhang J, Sun S, Guo H, Jia Z, Wang B, Shao Z, Wang Z, Hu X.

BMC Cancer. 2011 Jun 15;11:248. doi: 10.1186/1471-2407-11-248.


CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients.

Dietrich D, Krispin M, Dietrich J, Fassbender A, Lewin J, Harbeck N, Schmitt M, Eppenberger-Castori S, Vuaroqueaux V, Spyratos F, Foekens JA, Lesche R, Martens JW.

BMC Cancer. 2010 Jun 1;10:247. doi: 10.1186/1471-2407-10-247.


Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).

Bartlett JM, Munro AF, Dunn JA, McConkey C, Jordan S, Twelves CJ, Cameron DA, Thomas J, Campbell FM, Rea DW, Provenzano E, Caldas C, Pharoah P, Hiller L, Earl H, Poole CJ.

Lancet Oncol. 2010 Mar;11(3):266-74. doi: 10.1016/S1470-2045(10)70006-1.


CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.

Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Østenstad B, Lundgren S, Berge EO, Risberg T, Mjaaland I, Maehle L, Engebretsen LF, Lillehaug JR, Lønning PE.

PLoS One. 2008 Aug 26;3(8):e3062. doi: 10.1371/journal.pone.0003062.


PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients.

Hor SY, Lee SC, Wong CI, Lim YW, Lim RC, Wang LZ, Fan L, Guo JY, Lee HS, Goh BC, Tan T.

Pharmacogenomics J. 2008 Apr;8(2):139-46.


Resistance-associated signatures in breast cancer.

Györffy B.

Recent Results Cancer Res. 2007;176:37-50.


Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer.

Lee J, Im YH, Lee SH, Cho EY, Choi YL, Ko YH, Kim JH, Nam SJ, Kim HJ, Ahn JS, Park YS, Lim HY, Han BK, Yang JH.

Cancer Chemother Pharmacol. 2008 Apr;61(4):569-77.


Troponin-T and myoglobin plus echocardiographic evaluation for monitoring early cardiotoxicity of weekly epirubicin-paclitaxel in metastatic breast cancer patients.

Nisticò C, Bria E, Cuppone F, Carpino A, Ferretti G, Vitelli G, Sperduti I, Calabretta F, Toglia G, Tomao S, Cognetti F, Terzoli E.

Anticancer Drugs. 2007 Feb;18(2):227-32.


Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response.

Rody A, Karn T, Gätje R, Ahr A, Solbach C, Kourtis K, Munnes M, Loibl S, Kissler S, Ruckhäberle E, Holtrich U, von Minckwitz G, Kaufmann M.

Breast. 2007 Feb;16(1):86-93.


TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer.

Villman K, Sjöström J, Heikkilä R, Hultborn R, Malmström P, Bengtsson NO, Söderberg M, Saksela E, Blomqvist C.

Acta Oncol. 2006;45(5):590-6.


HER2 overexpression as a predictive marker in a randomized trial comparing adjuvant cyclophosphamide/methotrexate/5-fluorouracil with epirubicin in patients with stage I/II breast cancer: long-term results.

Colozza M, Sidoni A, Mosconi AM, Cavaliere A, Bisagni G, Gori S, De Angelis V, Frassoldati A, Cherubini R, Bian AR, Rodino C, Mazzocchi B, Mihailova Z, Bucciarelli E, Tonato M; Italian Oncology Group for Clincal Research..

Clin Breast Cancer. 2005 Aug;6(3):253-9.


HER2 expression and efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients.

Del Mastro L, Bruzzi P, Nicolò G, Cavazzini G, Contu A, D'Amico M, Lavarello A, Testore F, Castagneto B, Aitini E, Perdelli L, Bighin C, Rosso R, Venturini M.

Br J Cancer. 2005 Jul 11;93(1):7-14.


Overview of epirubicin-based adjuvant therapy in breast cancer.

Untch M, von Koch F, Kahlert S, Konecny G.

Clin Breast Cancer. 2000 Sep;1 Suppl 1:S41-5. Review.


Increased expression of BRCA1 mRNA predicts favorable response to anthracycline-containing chemotherapy in breast cancers.

Egawa C, Motomura K, Miyoshi Y, Takamura Y, Taguchi T, Tamaki Y, Inaji H, Koyama H, Noguchi S.

Breast Cancer Res Treat. 2003 Mar;78(1):45-50.


The European experience with docetaxel in the treatment of early-stage breast cancer.

Di Leo A.

Clin Breast Cancer. 2002 Oct;3 Suppl 2:S59-62. Review.


Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma.

Wang J, Buchholz TA, Middleton LP, Allred DC, Tucker SL, Kuerer HM, Esteva FJ, Hortobagyi GN, Sahin AA.

Cancer. 2002 Jun 15;94(12):3107-14.

Items per page

Supplemental Content

Loading ...
Support Center